{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T05:02:48Z","timestamp":1794718968620,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ajo.2026.08.028","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:11:49Z","timestamp":1787929909000},"page":"467-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALE"],"prefix":"10.1016","volume":"292","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-452X","authenticated-orcid":false,"given":"DILSHER S.","family":"DHOOT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAWRENCE J.","family":"SINGERMAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-4614","authenticated-orcid":false,"given":"PHILIP J.","family":"FERRONE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHARLES C.","family":"WYKOFF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ROGER A.","family":"GOLDBERG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9441-4356","authenticated-orcid":false,"given":"ROBYN H.","family":"GUYMER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ESTHER L.","family":"KIM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MATHEW W.","family":"MACCUMBER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANDR\u00c9","family":"MAIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SONG","family":"YU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FELIX","family":"YEMANYI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BRANDON A.","family":"COUGHLIN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CAROLINE R.","family":"BAUMAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FRANK G.","family":"HOLZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ajo.2026.08.028_bib0001","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/ceo.13834","article-title":"Retinal pigment epithelium and age-related macular degeneration: a review of major disease mechanisms","volume":"48","author":"Somasundaran","year":"2020","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.028_bib0002","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.mcna.2021.01.003","article-title":"Age-related macular degeneration","volume":"105","author":"Thomas","year":"2021","journal-title":"Med Clin North Am"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.028_bib0003","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"5\u2013a Suppl","key":"10.1016\/j.ajo.2026.08.028_bib0004","first-page":"S2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.028_bib0005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2026.08.028_bib0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","article-title":"Complement and its receptors: new insights into human disease","volume":"32","author":"Holers","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.028_bib0007","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1167\/iovs.12-9587","article-title":"Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration","volume":"53","author":"Loyet","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"17","key":"10.1016\/j.ajo.2026.08.028_bib0008","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1080\/14656566.2023.2257604","article-title":"The complement system: a novel therapeutic target for age-related macular degeneration","volume":"24","author":"Shughoury","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajo.2026.08.028_bib0009","unstructured":"Syfovre [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc.; 2024."},{"issue":"10411","key":"10.1016\/j.ajo.2026.08.028_bib0010","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.028_bib0011","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3928\/23258160-20250217-01","article-title":"Pegcetacoplan for geographic atrophy over 30 months: data from OAKS, DERBY, and the GALE long-term extension study","volume":"56","author":"Goldberg","year":"2025","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2026.08.028_bib0012","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ajo.2025.04.016","article-title":"Pegcetacoplan treatment for geographic atrophy in age-related macular degeneration over 36 months: data from OAKS, DERBY, and GALE","volume":"276","author":"Wykoff","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.08.028_bib0013","doi-asserted-by":"crossref","DOI":"10.2147\/OPTH.S579237","article-title":"Efficacy of continuous pegcetacoplan treatment for subfoveal geographic atrophy in age-related macular degeneration: 36-month results from OAKS, DERBY, and GALE open-label extension","volume":"20","author":"Dhoot","year":"2026","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.028_bib0014","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2026.08.028_bib0015","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.ophtha.2015.08.006","article-title":"Outcomes with as-needed ranibizumab after initial monthly therapy: long-term outcomes of the phase III RIDE and RISE trials","volume":"122","author":"Boyer","year":"2015","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.028_bib0016","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2026.08.028_bib0017","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2026.08.028_bib0018","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ophtha.2013.11.022","article-title":"Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials","volume":"121","author":"Thach","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.08.028_bib0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2025.02.012","article-title":"Visual function benefit after treatment with pegcetacoplan: microperimetry analysis from the phase 3 OAKS trial: microperimetry: visual function benefit with pegcetacoplan","volume":"273","author":"Chakravarthy","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.028_bib0020","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2006.09.016","article-title":"The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials","volume":"114","author":"Sunness","year":"2007","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2026.08.028_bib0021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/tvst.12.3.26","article-title":"Variation in retinal nerve fiber layer and ganglion cell complex associated with optic nerve head size in healthy eyes","volume":"12","author":"Li","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.ajo.2026.08.028_bib0022","unstructured":"US Food and Drug Administration. Summary review of NDA 217171 Syfovre. 2022. Accessed October 31, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/217171Orig1s000SumR.pdf."},{"issue":"9","key":"10.1016\/j.ajo.2026.08.028_bib0023","first-page":"1210","article-title":"Magnitude of clinically-meaningful effect size and preferences on treatment characteristics in the management of geographic atrophy (GA)","volume":"60","author":"Strecker","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.028_bib0024","first-page":"3400","article-title":"Foveal vs. total geographic atrophy as a predictor of visual acuity in AMD","volume":"58","author":"Bagheri","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.08.028_bib0025","unstructured":"Chang A, Dhoot DS, Goldberg RA, Singerman LJ, Baumal CR, Wykoff CC Clinical outcomes of early versus delayed pegcetacoplan treatment in GA: 48-month results from OAKS, DERBY, and GALE [oral presentation]. Presented at: 18th Congress of the Asia-Pacific Vitreo-Retina Society; December 12-14, 2025; Manila, Philippines."},{"issue":"6","key":"10.1016\/j.ajo.2026.08.028_bib0026","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/09286580591005723","article-title":"Modelling the natural history of geographic atrophy in patients with age-related macular degeneration","volume":"12","author":"Dreyhaupt","year":"2005","journal-title":"Ophthalmic Epidemiol"},{"issue":"6","key":"10.1016\/j.ajo.2026.08.028_bib0027","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and Spectri Phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2026.08.028_bib0028","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/aos.15796","article-title":"Multimodal imaging and deep learning in geographic atrophy secondary to age-related macular degeneration","volume":"101","author":"Pfau","year":"2023","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2026.08.028_bib0029","first-page":"2283","article-title":"Comparison of FAF and SD-OCT geographic atrophy lesion area and growth rate measurements","volume":"65","author":"Luu","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2026.08.028_bib0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.sjopt.2014.03.008","article-title":"Fundus autofluorescence imaging: fundamentals and clinical relevance","volume":"28","author":"Sepah","year":"2014","journal-title":"Saudi J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426004824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T09:03:22Z","timestamp":1794301402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426004824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":30,"alternative-id":["S0002939426004824"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.08.028","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Versus Delayed Pegcetacoplan Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration in OAKS, DERBY, and GALE","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}